Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$53.60 -0.4%	$47.35	$21.34 ▼ $58.40	$4.30B	-0.29	3.76 million shs	3.72 million shs
ARCT Arcturus Therapeutics	$21.57 +1.5%	$18.44	$8.04 ▼ $23.59	$577.03M	2.39	925,517 shs	1.15 million shs
ENTA Enanta Pharmaceuticals	$11.68 +6.6%	$8.97	$4.09 ▼ $15.34	$234.30M	0.89	1.57 million shs	417,085 shs
EPIX ESSA Pharma	$0.20	$0.63	$0.18 ▼ $6.45	$9.52M	1.57	2.99 million shs	N/A
PAHC Phibro Animal Health	$39.14 +4.0%	$36.32	$16.16 ▼ $41.57	$1.53B	0.83	264,627 shs	229,807 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+0.28%	+16.98%	+23.82%	+0.39%	+79.31%
ARCT Arcturus Therapeutics	+9.59%	+3.81%	+22.69%	+65.37%	+1.58%
ENTA Enanta Pharmaceuticals	-4.61%	-1.08%	+32.37%	+54.58%	-3.09%
EPIX ESSA Pharma	0.00%	-1.85%	-0.84%	-89.18%	-96.66%
PAHC Phibro Animal Health	+2.90%	+0.05%	-5.00%	+23.25%	+54.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$53.60 -0.4%	$47.35	$21.34 ▼ $58.40	$4.30B	-0.29	3.76 million shs	3.72 million shs
ARCT Arcturus Therapeutics	$21.57 +1.5%	$18.44	$8.04 ▼ $23.59	$577.03M	2.39	925,517 shs	1.15 million shs
ENTA Enanta Pharmaceuticals	$11.68 +6.6%	$8.97	$4.09 ▼ $15.34	$234.30M	0.89	1.57 million shs	417,085 shs
EPIX ESSA Pharma	$0.20	$0.63	$0.18 ▼ $6.45	$9.52M	1.57	2.99 million shs	N/A
PAHC Phibro Animal Health	$39.14 +4.0%	$36.32	$16.16 ▼ $41.57	$1.53B	0.83	264,627 shs	229,807 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+0.28%	+16.98%	+23.82%	+0.39%	+79.31%
ARCT Arcturus Therapeutics	+9.59%	+3.81%	+22.69%	+65.37%	+1.58%
ENTA Enanta Pharmaceuticals	-4.61%	-1.08%	+32.37%	+54.58%	-3.09%
EPIX ESSA Pharma	0.00%	-1.85%	-0.84%	-89.18%	-96.66%
PAHC Phibro Animal Health	+2.90%	+0.05%	-5.00%	+23.25%	+54.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	2.31	Hold	$73.38	36.89% Upside
ARCT Arcturus Therapeutics	2.90	Moderate Buy	$50.57	134.45% Upside
ENTA Enanta Pharmaceuticals	2.71	Moderate Buy	$20.83	78.37% Upside
EPIX ESSA Pharma	1.75	Reduce	$2.00	894.04% Upside
PAHC Phibro Animal Health	2.13	Hold	$28.40	-27.44% Downside

Current Analyst Ratings Breakdown

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2025	PAHC Phibro Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
10/13/2025	ARCT Arcturus Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
10/10/2025	AKRO Akero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$72.00 ➝ $54.00
10/10/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/10/2025	AKRO Akero Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/10/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/10/2025	AKRO Akero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$72.00 ➝ $54.00
10/10/2025	AKRO Akero Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Hold
10/9/2025	AKRO Akero Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/9/2025	AKRO Akero Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$75.00 ➝ $56.00
10/9/2025	AKRO Akero Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$73.00 ➝ $54.00

(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
ARCT Arcturus Therapeutics	$152.31M	3.85	N/A	N/A	$8.90 per share	2.42
ENTA Enanta Pharmaceuticals	$64.81M	3.85	N/A	N/A	$6.08 per share	1.92
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
PAHC Phibro Animal Health	$1.30B	1.22	$3.40 per share	11.51	$7.05 per share	5.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	11/14/2025 (Estimated)
ARCT Arcturus Therapeutics	-$80.94M	-$2.23	N/A	N/A	N/A	-49.26%	-24.87%	-17.75%	11/6/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.32	N/A	N/A	N/A	-141.98%	-89.02%	-27.28%	12/1/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.56	N/A	N/A	N/A	N/A	-21.71%	-21.22%	12/16/2025 (Estimated)
PAHC Phibro Animal Health	$48.26M	$1.18	33.17	18.64	1.14	3.73%	32.14%	6.89%	11/5/2025 (Estimated)

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2025	Q3 2025	ARCT Arcturus Therapeutics	-$1.09	N/A	N/A	N/A	$17.47 million	N/A
11/5/2025	Q1 2026	PAHC Phibro Animal Health	$0.58	N/A	N/A	N/A	$345.44 million	N/A
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	$0.57	+$0.05	$0.42	$362.24 million	$378.70 million
8/13/2025	Q3 2025	EPIX ESSA Pharma	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	-$0.34	+$0.77	-$0.34	$17.64 million	$28.30 million
8/11/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.25	-$0.85	+$0.40	-$0.85	$16.21 million	$18.31 million
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	$1.69	839.96%	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.23%	N/A	40.68%	N/A

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.26%	9/3/2025	9/3/2025	9/24/2025
1/1/2100	EPIX ESSA Pharma	--	$1.69		8/25/2025	8/19/2025	8/22/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.02	12.66	12.66
ARCT Arcturus Therapeutics	N/A	5.90	5.90
ENTA Enanta Pharmaceuticals	N/A	5.00	5.00
EPIX ESSA Pharma	N/A	69.06	69.06
PAHC Phibro Animal Health	2.46	2.76	1.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
ARCT Arcturus Therapeutics	94.54%
ENTA Enanta Pharmaceuticals	94.99%
EPIX ESSA Pharma	75.12%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
ARCT Arcturus Therapeutics	16.60%
ENTA Enanta Pharmaceuticals	13.89%
EPIX ESSA Pharma	15.50%
PAHC Phibro Animal Health	50.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
ARCT Arcturus Therapeutics	180	27.16 million	22.65 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
EPIX ESSA Pharma	50	47.31 million	39.98 million	Optionable
PAHC Phibro Animal Health	2,475	40.53 million	20.21 million	Optionable

ENTA, PAHC, ARCT, AKRO, and EPIX Headlines

Recent News About These Companies

Phibro Animal Health's (PAHC) "Hold (C)" Rating Reiterated at Weiss Ratings

October 14 at 2:42 PM | marketbeat.com

Q1 EPS Forecast for Phibro Animal Health Lifted by Analyst

October 12 at 2:25 AM | americanbankingnews.com

Revisiting Phibro Animal Health (PAHC) Valuation Following Recent Share Price Swings

October 11, 2025 | finance.yahoo.com

Q1 EPS Estimate for Phibro Animal Health Lifted by Analyst

October 11, 2025 | marketbeat.com

Zacks Research Issues Pessimistic Forecast for PAHC Earnings

October 11, 2025 | americanbankingnews.com

PAHC or BSX: Which Is the Better Value Stock Right Now?

October 10, 2025 | zacks.com

Q2 EPS Forecast for Phibro Animal Health Lowered by Analyst

October 10, 2025 | marketbeat.com

Phibro Animal Health announces licensing pact with Lighthouse Pharmaceuticals

October 10, 2025 | msn.com

Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs

October 9, 2025 | businesswire.com

Why Phibro Animal Health (PAHC) is a Top Growth Stock for the Long-Term

October 9, 2025 | msn.com

Should You Continue to Hold Bio-Techne Stock in Your Portfolio?

October 8, 2025 | zacks.com

New Strong Buy Stocks for October 7th

October 7, 2025 | zacks.com

Best Income Stocks to Buy for October 7th

October 7, 2025 | zacks.com

Phibro Animal Health Corporation (PAHC) Soars 39% in Q4, Stock Up 80% YTD on Zoetis Acquisition Boost

October 1, 2025 | finance.yahoo.com

Phibro Animal Health (NASDAQ:PAHC) Upgraded at Zacks Research

October 1, 2025 | marketbeat.com

Is There An Opportunity With Phibro Animal Health Corporation's (NASDAQ:PAHC) 50% Undervaluation?

September 30, 2025 | finance.yahoo.com

New Strong Buy Stocks for September 30th

September 30, 2025 | zacks.com

Q3 EPS Estimate for Phibro Animal Health Boosted by Analyst

September 29, 2025 | marketbeat.com

Why Is Phibro (PAHC) Down 1.1% Since Last Earnings Report?

September 26, 2025 | msn.com

Phibro Animal Health Corporation $PAHC Shares Acquired by Voya Investment Management LLC

September 26, 2025 | marketbeat.com

Phibro Animal Health Stock Surges 82.1% YTD: What's Fueling It?

September 25, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENTA, PAHC, ARCT, AKRO, and EPIX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$53.60 -0.21 (-0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$53.71 +0.11 (+0.20%)

As of 08:00 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Arcturus Therapeutics NASDAQ:ARCT

$21.57 +0.32 (+1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$21.58 +0.02 (+0.07%)

As of 07:37 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Enanta Pharmaceuticals NASDAQ:ENTA

$11.68 +0.72 (+6.57%)

Closing price 04:00 PM Eastern

Extended Trading

$11.67 -0.01 (-0.09%)

As of 07:50 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ESSA Pharma NASDAQ:EPIX

$0.20 0.00 (0.00%)

As of 10/13/2025

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Phibro Animal Health NASDAQ:PAHC

$39.14 +1.50 (+3.99%)

Closing price 04:00 PM Eastern

Extended Trading

$39.16 +0.02 (+0.05%)

As of 07:05 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Earnings

Compare Dividends

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTA, PAHC, ARCT, AKRO, and EPIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENTA, PAHC, ARCT, AKRO, and EPIX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

Arcturus Therapeutics NASDAQ:ARCT

Enanta Pharmaceuticals NASDAQ:ENTA

ESSA Pharma NASDAQ:EPIX

Phibro Animal Health NASDAQ:PAHC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools